{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:27:45Z","timestamp":1790483265700,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NIH","award":["DK34989"],"award-info":[{"award-number":["DK34989"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>New and more promising therapies for chronic hepatitis C (<jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content>) genotype 1 (G1) naive patients have recently been approved in the United States and Europe, and several more regimens are expected to become available within the next several years. While this scenario unfolds, it is necessary to develop a rational method to allocate current treatment in<jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content>G1 patients. We performed a cost\u2010effectiveness analysis of boceprevir (<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>)\u2010 and telaprevir (<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>)\u2010based triple therapy according to different patients\u2019 selection strategies. A semi\u2010Markov model of<jats:styled-content style=\"fixed-case\">CHC<\/jats:styled-content>natural history and progression towards end\u2010stage liver disease was built. We considered 3 selection strategies based on<jats:styled-content style=\"fixed-case\">METAVIR<\/jats:styled-content>fibrosis stage: (i) treat all patients with F1\u2013F4 fibrosis, (ii) only F2\u2013F4 and (iii) only F3\u2013F4. For each strategy,<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>interleukin\u201028B\u2010guided (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>28B\u2010guided) and<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>rapid virologic response\u2010guided (RVR\u2010guided) therapies were applied. The model assessed the costs and outcomes, using a lifetime and 5\u2010year time horizon, and adopting the Italian National Health System perspective. The incremental cost\u2010effectiveness ratio (<jats:styled-content style=\"fixed-case\">ICER<\/jats:styled-content>) for F1\u2013F4 strategy relative to F3\u2013F4 was \u20ac5132 per quality\u2010adjusted life years gained, across<jats:styled-content style=\"fixed-case\">TVR IL<\/jats:styled-content>\u201028B\u2010guided therapy, and \u20ac7042 in the<jats:styled-content style=\"fixed-case\">BOC RVR<\/jats:styled-content>\u2010guided therapy. Conversely, in the 5\u2010year scenario, the<jats:styled-content style=\"fixed-case\">ICER<\/jats:styled-content>for F1\u2013F4 strategy relative to F3\u2013F4 was \u20ac1\u00a0818\u00a0679 (<jats:styled-content style=\"fixed-case\">TVR IL<\/jats:styled-content>28B\u2010guided) and \u20ac1\u00a0866\u00a0437 (<jats:styled-content style=\"fixed-case\">BOC RVR<\/jats:styled-content>\u2010guided) per end\u2010stage liver disease or death (<jats:styled-content style=\"fixed-case\">ESLD<\/jats:styled-content>\u2010D) avoided. In view of anticipated improvement in the efficacy of future regimens, selective treatment of only patients with advanced fibrosis and cirrhosis with<jats:styled-content style=\"fixed-case\">TVR<\/jats:styled-content>or<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>could represent the most cost\u2010effective strategy to optimize resource utilization.<\/jats:p>","DOI":"10.1111\/jvh.12278","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T09:35:45Z","timestamp":1404984945000},"page":"175-183","source":"Crossref","is-referenced-by-count":18,"title":["Management of treatment\u2010na\u00efve chronic hepatitis<scp>C<\/scp>genotype 1 patients: a cost\u2010effectiveness analysis of treatment options"],"prefix":"10.1111","volume":"22","author":[{"given":"P. A.","family":"Cortesi","sequence":"first","affiliation":[{"name":"Research Centre on Public Health (CESP) University of Milan\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"Department of Surgical and Interdisciplinary Medicine University of Milan\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rota","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Centre of Biostatistics for Clinical Epidemiology University of Milan\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. K.","family":"Lim","sequence":"additional","affiliation":[{"name":"Liver Center &amp; Section of Digestive Diseases Department of Internal Medicine Yale University School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Salvia","sequence":"additional","affiliation":[{"name":"Department of Surgical and Interdisciplinary Medicine University of Milan\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Okolicsanyi","sequence":"additional","affiliation":[{"name":"Department of Surgical and Interdisciplinary Medicine University of Milan\u2010Bicocca Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vinci","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Liver Unit Niguarda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Belli","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Liver Unit Niguarda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. G.","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery University Federico II of Naples Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Strazzabosco","sequence":"additional","affiliation":[{"name":"Department of Surgical and Interdisciplinary Medicine University of Milan\u2010Bicocca Monza Italy"},{"name":"Liver Center &amp; Section of Digestive Diseases Department of Internal Medicine Yale University School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07642-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21492"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00005"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25734"},{"key":"e_1_2_8_10_1","unstructured":"FDA.Food and Drug Administration[Internet]. Available at:http:\/\/www.fda.gov\/forconsumers\/byaudience\/forpatientadvocates\/ucm377920.htm(accessed 11 December 2013)."},{"key":"e_1_2_8_11_1","unstructured":"FDA.Food and Drug Administration[Internet]. Available at:http:\/\/www.fda.gov\/forconsumers\/byaudience\/forpatientadvocates\/ucm377234.htm(accessed 11 December 2013)."},{"issue":"1","key":"e_1_2_8_12_1","first-page":"1195A","article-title":"Generation and Performance of Outcome Indicators in Liver Disease: the Value Based Medicine in Hepatology Study (V.B.M.H.)","volume":"58","author":"Okolicsanyi S","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_8_13_1","unstructured":"Italian National Institute of Statistics (ISTAT)[Internet]. Available at:http:\/\/demo.istat.it\/(accessed 15 May 2013)"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir306"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045066"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"s567","volume":"58","author":"Vierling JM","year":"2013","journal-title":"J Hepatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12314"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.1131"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.04.008"},{"key":"e_1_2_8_23_1","unstructured":"Italian National Institute of Statistics (ISTAT)[Internet]. Available at:http:\/\/dati.istat.it\/Index.aspx(accessed 15 May 2013)"},{"key":"e_1_2_8_24_1","unstructured":"National agency for regional healthcare services (AGENAS)[internet]. Available at:http:\/\/www.agenas.it\/(accessed 15 May 2013)"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost\u2010Effectiveness in Health and Medicine","author":"Gold MR","year":"1996"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)61371-8"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04370.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.005"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32418"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60039-7"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.11.022"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12278","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T14:04:31Z","timestamp":1716991471000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/jvh.12278"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12278","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,10]]}}}